The American Diabetes Association has called on manufacturers of incretin therapies to disclose all patient-level data on their products for an independent analysis that would help determine if such treatments play a role in pancreatic cancer. AstraZeneca and Bristol-Myers Squibb expressed support for the ADA's call, noting in a joint statement that they look forward to a discussion with the group about its proposal.

Related Summaries